Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, today announced their merger to form Calluna Pharma Inc. (Calluna).

SPACE-H Accelerator to Explore Astronaut Disease Treatment in Space

What You Should Know: – NaNotics LLC, a biopharmaceutical company developing NaNots® – novel subtractive nanoparticles that treat disease by capturing and clearing pathogenic molecules from

September 27, 2024

IVF Executive Order a Good Start, but Not Enough, Women’s Healthcare Groups Say

Healthcare groups whose members treat patients with infertility are somewhat pleased with President Trump’s executive order aimed at increasing access to in vitro fertilization (IVF),

February 22, 2025

Vascular changes in brain trauma could trigger Alzheimer’s development

An increased risk of dementia among individuals exposed to brain trauma, traumatic brain injury, has been known for almost a century.

February 12, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.